B. Riley analyst Madison El-Saadi last night initiated coverage of Wave Life Sciences with a Buy rating and $11 price target. Wave is pioneering “multiple differentiated” RNA-based modalities, namely allele-selective silencing and RNA-editing, which each represent a new branch of RNA-based medicines that are stereochemically pure with a PN-modified backbone, the analyst tells investors in a research note. The firm believes the company’s platform has the potential to progress medicines across multiple tissue verticals while attracting significant investment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences initiated with a Buy at B. Riley
- Biotech Alert: Searches spiking for these stocks today
- Wave Life Sciences treatment of Duchenne muscular dystrophy gets orphan status
- 3 Best Stocks to Buy Now, 9/9/2024, According to Top Analysts
- Wave Life Sciences initiated with an Overweight at JPMorgan